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Abstract
Background: The clinical utility of testing for antiphospholipid antibodies (aPL) of IgA isotype remains controversial.
Methodology/Principal Findings: To address this issue, we reasoned that if IgA aPL contribute to the clinical manifestations
of the antiphospholipid syndrome, then an association with thromboembolic events should manifest in patients whose only
aPL is of IgA isotype. We performed a retrospective chart review of 56 patients (31 with systemic lupus erythematosus [SLE]
and 25 without SLE) whose only positive aPL was IgA anti-b2-glycoprotein I (isolated IgA anti-b2GPI) and compared their
clinical features with 56 individually matched control patients without any aPL. Patients with isolated IgA anti-b2GPI had a
significantly increased number of thromboembolic events, as compared to controls. When patients were stratified into
those with and without SLE, the association between isolated IgA anti-b2GPI and thromboembolic events persisted for
patients with SLE, but was lost for those without SLE. Titers of IgA anti-b2GPI were significantly higher in SLE patients who
suffered a thromboembolic event. Among patients with isolated IgA anti-b2GPI, there was an increased prevalence of
diseases or morbidities involving organs of mucosal immunity (i.e., gastrointestinal system, pulmonary system, and skin).
Conclusions/Significance: The presence of isolated IgA anti-b2GPI is associated with an increased risk of thromboembolic
events, especially among patients with SLE. IgA anti-b2GPI is associated with an increased prevalence of morbidities
involving organs of mucosal immunity.
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Introduction
The clinical utilityof testing for antiphospholipidantibodies (aPL)
of IgA isotype remains controversial. According to the international
consensus statement on antiphospholipid syndrome (APS), aPL of
IgA isotype (either anticardiolipin antibodies [aCL] or anti-b2-
glycoprotein I antibodies [anti-b2GPI]) do not fulfill laboratory
criteria for APS classification [1]. This exclusion was based on the
opinion that these autoantibodies lack specificity and do not provide
independent clinical information from that given by IgM or IgG
aPL. However, in certain cohorts, many individuals test positive for
IgAaPLalone orwithother aPL [1–18]. Patients withIgAaPLonly
are particularly important, as they cannot be classified as having
APS even when manifesting APS symptoms.
To determine whether IgA aPL are associated with clinical
manifestations, we used an approach that differs from previous
studies. We reasoned that if IgA aPL contribute to APS
manifestations, then thromboembolic events should manifest in
patients with isolated IgA aPL. These patients do not manifest any
other aPL, including non-IgA aPL or lupus anticoagulant (LA)
activity, associated with APS. Therefore, we performed a retrospec-
tive chart review of patients with isolated IgA anti-b2GPI and
compared their clinical features with individually matched controls to
determine whether isolated IgA anti-b2GPI is associated with an
increased risk for thromboembolic events, especially within a
background of systemic lupus erythematosus (SLE).
Materials and Methods
Ethics
The medical records of patients and controls were reviewed
according to a study protocol approved by the University of
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12280Chicago Institutional Review Board. Patient consent was waived,
as this was a retrospective chart review and no therapeutic
interventions were involved.
Participants
We performed a retrospective review of the laboratory results of
allpatientswho underwent completeaPLtestingattheUniversityof
Chicago Hospital between November, 2001, and July, 2007.
Complete aPL testing was defined as including all of the following:
aCL (IgM, IgG, and IgA); anti-b2GPI (IgM, IgG, and IgA); and LA
(activated partial thromboplastin time [aPTT], dilute Russell viper
venom time [dRVVT], and tissue thromboplastin inhibition test
[TTI]). Of 5602 patients who underwent complete aPL testing, we
identified 56 (1%) whose only positive aPL was IgA anti-b2GPI: 31
patients with SLE and 25 patients without SLE. It should be
emphasized that these 56 patients with an isolated IgA anti-b2GPI
(hereafter called ‘‘isolated IgA anti-b2GPI’’) were negative for IgA
aCL. An additional 21 of the 5602 patients were positive for IgA
anti-b2GPI, but had concomitant elevation of one or more other
aPLand weretherefore not included (5 IgM aCL; 2 IgG aCL; 3 IgA
aCL; 2 IgM plus IgA aCL; 2 IgG plus IgA aCL; 1 IgM plus IgG
aCL; 2 IgM, IgG, plus IgA aCL; and 4 LA). No patients who
underwent complete aPL testing or who had isolated IgA anti-
b2GPI were excluded. Controls were individuals who underwent
complete aPL testing and were negative for all aPL. They were
individually matched to patients based on age, gender, race, and
disease status (32 with and 24 without SLE). SLE was defined
according to American College of Rheumatology (ACR) criteria
[19]. As patients in our study were positive for IgA anti-b2GPI, but
negative for all other aPL, SLE status was unchangedby application
of the revised ACR criteria, which include aPL positivity [20].
Clinical data
Clinical data at baseline included demographic parameters (age,
gender, and race); general comorbidities (hypertension and
diabetes mellitus); SLE status; history of pregnancy morbidity;
occurrence of arterial, venous, and/or microvascular thrombo-
embolic events; medication history; and comorbidities of organs or
tissues involved in mucosal immunity (gastrointestinal [GI] system,
pulmonary system, or skin).
Arterial events included cerebrovascular accident (CVA), tran-
sient ischemic attack (TIA), myocardial infarction (MI), angina, or
other acute events involving the arterial vasculature. Venous events
included deep vein thrombosis (DVT), pulmonary embolism (PE),
or other acute events involving the venous vasculature. Microvas-
cular events included biopsy-proven thrombotic microangiopathy
(TMA). Criteria for thromboembolic events included confirmatory
diagnostic tests and/or documented clinical diagnoses by treating
physicians. Patients had no previous medical history of thrombosis,
asconfirmedbythetreating physiciananddocumentedinphysician
notes. Only confirmed events were used in our analyses. Criteria for
comorbidities involving the GI system, pulmonary system, or skin
included confirmatory diagnostic tests and/or documented clinical
diagnoses by treating physicians. Specific etiologies for comorbid-
ities were not required.
aPL assays
All testing for aPL was performed by the University of Chicago
clinical laboratories, according to instructions by the assay’s
manufacturer. Levels of anti-b2GPI were determined by ELISA
using separate QUANTA Lite Test Kits for IgG, IgM, and IgA
isotypes (B2-GPI IgG ELISA, B2-GPI IgM ELISA, and B2-GPI
IgA ELISA; INOVA Diagnostics, Inc., San Diego, CA). Levels of
aCL were determined by ELISA using QUANTA Lite Test Kits
for IgG, IgM, and IgA isotypes (ACA IgM III, ACA IgG III, and
ACA IgA III; INOVA Diagnostics, Inc.). aPTT was determined
using the Sta PTT Automate 5 and PTT-LA assay kits
(Diagnostica Stago, Parsippany, NJ). dRVVT was determined by
LA Screen and LA confirm assay kits (LASD-25 and LACD-10;
Rainbow Scientific Inc., Windsor, CT). TTI was determined using
the Sta Neoplastine CL +10 reagent (Diagnostica Stago).
The cutoff between positive and negative samples for all aPL
assays was established as described in the respective kits. We
defined a positive aPL test as a single measurement that fell outside
the normal reference range: aCL (IgM $15.7 U/mL, IgG
$19.3 U/ml, IgA $8.2 U/mL); anti-b2GPI (IgM $20 U/ml,
IgG $20 U/ml, IgA $20 U/mL); and LA (aPTT $46 secs,
dRVVT $40 secs, TTI $1.4).
Statistical methods
Continuous variables, expressed as mean 6 standard error,
were compared by the median test or Wilcoxon rank-sum test.
Categorical variables were compared by Fisher’s exact test or
McNemar’s test between matched-paired data. SASH software was
used for statistical analyses and P,0.05 was considered statistically
significant.
Results
Clinical characteristics
The majority of the 56 patients with isolated IgA anti-b2GPI
were female (89%) and African-American (70%), with a mean age
of 43 years. Thirty-one patients with isolated IgA anti-b2GP had
SLE, while 25 did not. The titer of IgA anti-b2GPI was mildly
elevated (20–50 U/mL) in 32 patients, moderately elevated (50–
100 U/mL) in 15, and severely elevated (.100 U/mL) in 9.
There were 38 total thromboembolic events (23 arterial, 10
venous, and 5 TMA) in 27 patients (48%), of whom 15 had SLE.
Control individuals underwent complete aPL testing and were
negative for all aPL. In controls, there were 18 total thromboem-
bolic events (12 arterial, 6 venous) in 14 patients (25%), of whom 4
had SLE (Table 1). SLE disease duration did not differ between
patients and controls (5.963.0 years vs. 6.864.8 years, p.0.5).
Twenty-three of the 56 patients with isolated IgA anti-b2GPI
had repeat aPL testing, and, of these, 21 had persistently positive
IgA anti-b2GPI. Thromboembolism occurred in 13 (62%) of the
patients with persistently elevated IgA anti-b2GPI.
Isolated IgA anti-b2GPI is associated with an increased
risk of thromboembolic events
Isolated IgA anti-b2GPI was associated with an increased risk of
thromboembolic events in the 56 patients with and without SLE
(p=0.018, odds ratio [OR]=2.793, 95% confidence interval
[CI]=1.263–6.172). When we restricted our analysis to patients
with SLE, isolated IgA anti-b2GPI was still associated with an
increased risk (p=0.026, OR=4.282, 95% CI=1.338–13.569).
In contrast, among non-SLE patients, isolated IgA anti-b2GPI was
not associated with an increased risk of thromboembolic events
(p=0.773, OR=1.397, 95% CI=0.456–4.276). These data
(Table 2) indicate that IgA anti-b2GPI is associated with an
increased risk of thromboembolic events in the presence, but not
absence, of SLE.
Higher titers of IgA anti-b2GPI are associated with a
greater risk for thromboembolic events in SLE patients
We next determined whether thromboembolic event occurrence
correlated with higher median titers of IgA anti-b2GPI. Among
aPLs and Thromboembolic Events
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found in patients who had suffered a thromboembolic event
(73.1611.2 vs. 47.868.1 U/ml, p=0.0262). Although a similar
trend was observed among all patients with isolated IgA anti-
b2GPI, it was not statistically significant (65.268.2 vs.
53.567.2 U/ml, p=0.0926). No association between higher titers
and thromboembolic event occurrence was found among non-
SLE patients with isolated IgA anti-b2GPI (55.4611.8 vs.
60.2612.7 U/ml, p=0.4253).
Among individuals with and without isolated IgA anti-b2GPI,
there were no significant differences with respect to prevalence of
hypertension, use of oral contraceptives, or level of proteinuria.
Incomplete data within the medical records of patients and
controls precluded analysis of other factors linked to thrombosis,
such as smoking, homocycteine levels, other thrombophilic
disorders, and hydroxychloroquine use.
Isolated IgA anti-b2GPI is associated with an increased
prevalence of co-morbidities involving the mucosal
immune system
IgA antibodies are associated with disorders or diseases
involving the organs of mucosal immunity, predominantly the
GI system, pulmonary system, and skin. Secretion of IgA at the
mucosal surface of these organs binds specifically to pathogens and
inhibits their entry into the body. Isotype switching to IgA is
induced by local factors produced within the lymphoid tissues of
these organs.
We therefore determined whether isolated IgA anti-b2GPI was
associated with the presence of co-morbidities involving organs of
mucosal immunity. Patients and matched controls were stratified
according to the number of organs of mucosal immunity affected
by at least one co-morbidity. Patients with isolated IgA anti-b2GPI
typically had involvement of two or three mucosal organs, whereas
the controls had fewer (no or one) co-morbidities (Figure 1)
(p=0.0021). When patients were stratified according to the
presence or absence of at least one affected organ of mucosal
immunity, patients with involvement of at least one mucosal organ
were more likely to have isolated IgA anti-b2GPI antibodies
(Table 2) (p=0.0095, OR=3.595, 95% CI=1.394–9.223).
Moreover, the mean number of mucosal organs affected by a
co-morbidity was significantly greater among patients with isolated
IgA anti-b2GPI (1.6160.12 vs. 1.0560.14, p=0.007), as
compared to those without isolated IgA anti-b2GPI. We also
evaluated the association between isolated IgA anti-b2GPI and
each individual organ of mucosal immunity. While there was a
trend towards increased risk of involvement for each organ among
Table 1. Clinical characteristics of patients (stratified according to IgA anti-b2GPI titer) and controls.
Patients with isolated IgA anti-b2GPI Controls
Mild elevation (20–
49 U/mL)
Moderate elevation (50–
99 U/mL)
Severe elevation
($100 U/ml) Total Total
Number of patients (%) 32 (57%) 15 (27%) 9 (16%) 56 (100%) 56
Age (range) 43.3 years (22–78) 40.8 years (24–68) 44.4 years (30–61) 42.8 years (22–78) 42.8 years (22–78)
Race
African-American 22 12 5 39 39
Asian 1 0 0 1 1
Caucasian 4 1 2 7 7
Hispanic 1 0 0 1 1
Unknown 4 2 2 8 8
Gender
Female 30 13 7 50 50
Male 2 2 2 6 6
Thromboembolic events
{
Number of patients (%) 13 (41%) 10 (67%) 4 (44%) 27 (48%) 14 (25%)
Total Events 17 14 7 38 18
Arterial Events 10 8 5 23 12
Venous Events 5 3 2 10 6
TMA* 2 3 0 5 0
SLE* status
SLE 16 11 4 31 32
Non-SLE
# 16 4 5 25 24
*Abbreviations used in this table: SLE, systemic lupus erythematosus; TMA, thrombotic microangiopathy.
{Among IgA anti-b2GPI positive patients, 5 had both an arterial and a venous event (3 with mild elevation, 1 with moderate elevation, 1 with severe elevation), 4
patients had both an arterial event and TMA (2 with mild elevation, 2 with moderate elevation), 1 patient had both a venous event and TMA (with moderate elevation),
and 1 patient had 2 arterial events (with severe elevation). Among controls, 4 had both an arterial and a venous event.
#Among IgA anti-b2GPI positive patients, non-SLE patients included the following autoimmune or rheumatologic diagnoses: Cogan’s syndrome (n=1), fibromyalgia
(n=1), Hashimoto’s thyroiditis (n=1), mixed connective tissue disease (n=1), myelitis (n=1), polycystic ovary syndrome (n=1), sarcoidois (n=1), scleroderma (n=1),
sickle cell anemia (n=2), Sjo ¨gren’s syndrome (n=1), Tietze’s syndrome (n=1), and Wegener’s granulomatosis (n=1). Among controls, non-SLE individuals included:
amyotrophic lateral sclerosis (n=1), Behcet’s syndrome (n=1), chondrocalcinosis (n=1), HELLP syndrome (n=1), inflammatory polyarthropathy (n=1), osteoporosis
(n=1), Raynaud’s disease (n=1), Sjo ¨gren’s syndrome (n=2), and ulcerative colitis (n=1).
doi:10.1371/journal.pone.0012280.t001
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p=0.078; GI: 44.6% vs. 28.6%, p=0.116; skin: 62.5% vs. 48.2%,
p=0.183), the results did not achieve statistical significance. The
specific comorbidities affecting each mucosal organ are given in
Table 3.
Discussion
The utility of testing for IgA aPL is unclear and highly
controversial. While some studies have found an association
between IgA aPL and the clinical manifestations of APS
[1,2,6,7,9,10,12–17], others have reported no association
[4,5,8,11,18]. Here, we have determined whether IgA aPL are
associated with clinical manifestations using an approach that
differs from previous studies. We reasoned that if IgA aPL
contribute to clinical manifestations of APS, then an association
with thromboembolic events should manifest in patients whose
only aPL is IgA. We limited our analysis to patients for whom IgA
anti-b2GPI was the only aPL present. These patients and controls
were also negative for IgA aCL. By restricting our analysis to
isolated IgA anti-b2GPI, we limited the potentially confounding
influence of other aPL specificities and isotopes on our results. A
retrospective chart review of 56 patients with isolated IgA anti-
b2GPI was performed, and the clinical features of these patients
were compared with 56 individually matched control patients
without aPL.
Our results add to the growing evidence that patients with IgA
aPL are at increased risk for thromboembolic events. First, we
found that patients with isolated IgA anti-b2GPI had significantly
more thromboembolic events than controls. Second, among
patients with isolated IgA anti-b2GPI, those with at least one
thromboembolic event had significantly higher titers of IgA anti-
b2GPI than patients without a thromboembolic event. Third,
isolated IgA anti-b2GPI presence was associated with an increased
prevalence of diseases or morbidities involving organs of mucosal
immunity. Finally, when patients were stratified into those with
and without SLE, the association between isolated IgA anti-b2GPI
and thromboembolic events persisted for patients with SLE, but
was lost for those without SLE.
The lack of association between isolated IgA anti-b2GPI and
thromboembolic events among non-SLE patients requires com-
ment. Two methodological issues may have contributed to this
negative result. The first is our limited study size. Insufficient
power may have precluded detection of an association among
non-SLE patients, especially if the risk conferred by isolated IgA
anti-b2GPI is less for non-SLE than SLE patients. The second
issue relates to a potential bias in non-SLE patient selection.
Although patients and controls were selected on the basis of
laboratory records for aPL testing and individually matched, the
rationale for aPL testing may have differed for SLE versus non-
SLE patients. For SLE patients, aPL testing is typically conducted
within a screen for SLE-associated autoantibodies. In contrast, for
non-SLE patients, aPL testing would more likely be performed
because of suspected hypercoagulability. Thus, non-SLE patients
lacking IgA anti-b2GPI may have been biased towards an
increased prevalence of thromboembolic events (i.e., the outcome
measured). This potential bias is apparent when comparing the
frequency of patients with at least one thromboembolic event in
non-SLE versus SLE controls (i.e., patients lacking aPL) (non-SLE:
36% vs. SLE: 16%). In contrast, among patients with isolated IgA
Table 2. Prevalence of thromboembolic events and mucosal organ involvement in patients with isolated IgA anti-b2GPI versus
controls.
Thromboembolic events
Isolated IgA anti-
b2GPI Controls Odd ratio 95% CI p value
Entire cohort (n=56)
$1 thromboembolic event 27 14 2.793 1.263–6.172 0.018
No thromboembolic event 29 42
SLE (n=31)
$1 thromboembolic event 14 5 4.282 1.338–13.569 0.026
No thromboembolic event 17 26
Non-SLE (n=25)
$1 thromboembolic event 11 9 1.397 0.456–4.276 0.773
No thromboembolic event 14 16
Mucosal organ involvement
$1 mucosal organs 49 37 3.595 1.394–9.223 0.013
No mucosal organs 7 19
doi:10.1371/journal.pone.0012280.t002
Figure 1. The presence of isolated IgA anti-b2GPI is associated
with increased clinical involvement of the mucosal immune
system (GI system, pulmonary system, or skin). Depicted are the
total number of patients (IgA anti-b2GPI-positive) and controls (aPL-
negative) who had a co-morbidity or disease involving 0, 1, 2, or 3
organs of mucosal immunity.
doi:10.1371/journal.pone.0012280.g001
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thromboembolic event is more closely matched in non-SLE versus
SLE patients (non-SLE: 44% vs. SLE: 45%), suggesting the
predominating effect of aPL.
There are several reasons why the concomitant presence of SLE
may increase the risk of thromboembolism in patients with isolated
IgA anti-b2GPI. First, SLE may confer an increased risk for
thrombosis that is independent from that of aPL [21,22]. Second,
concurrent inflammation and activation of innate immunity
during flares of SLE may provide a ‘‘second hit’’ necessary for
aPL to induce thrombosis [23]. Third, the epitope specificity of
IgA anti-b2GPI may differ depending upon whether aPL arise in
the presence or absence of systemic autoimmunity. For example,
among anti-b2GPI, antibodies that recognize domain I of b2GPI
are predictive of thrombosis, whereas those that recognized other
domains are not [24]. Finally, other autoantibodies found in SLE
patients, such as anti-heat shock protein 60 antibodies, may
interact with aPL to enhance thrombotic potential [25,26].
Our study has several limitations, in addition to its small sample
size and possible selection bias for non-SLE patients. First, the
Table 3. Comorbidities involving organs of mucosal immunity in patients with isolated IgA anti-b2GPI titer versus controls.
Comorbidities by Organ System Patients with isolated IgA anti-b2GPI Controls
Gastrointestinal system Total 25 Total 16
GERD 14 11
Gastric/duodenal ulcers 4 0
Cholecystitis 2 0
Diarrhea 2 0
Hepatitis 1 0
Pancreatitis 1 2
Gastrointestinal bleed 1 1
IBD/ulcerative colitis 0 2
Pulmonary system Total of 26 Total 16
Asthma 11 6
Interstitial lung disease 4 3
Pleuritis 3 0
Restrictive lung disease 2 0
Sleep apnea 2 0
Emphysema 1 0
Lung mass 1 0
Aspiration 1 0
Sarcoidosis 1 0
Bronchitis 0 1
COPD 0 3
Pulmonary hemorrhage 0 1
ARDS 0 1
Pleural effusion 0 1
Skin Total 35 Total 27
Rash 15 11
Cutaneous lupus 7 9
Herpes zoster 5 2
Varicose veins 1 0
Livedo reticularis 1 0
Alopecia 1 0
Cutaneous ulcers 1 0
Skin cancer 1 1
Cutaneous sarcoid 1 0
Keloid 1 1
Vitiligo 1 0
Raynaud’s 0 2
Psoriasis 0 1
*Abbreviations used in this table: ARDS, adult respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; GERD, gastro-esophageal reflux disease; IBD,
inflammatory bowel disease.
doi:10.1371/journal.pone.0012280.t003
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complete data on several non-aPL-related risk factors for
thrombosis, such as smoking, homocycteine levels, and other
thrombophilic disorders. In addition, many patients did not
undergo repeat testing for aPL, so we could not determine if IgA
anti-b2GPI were transient or persistent.
In conclusion, our data indicate that IgA anti-b2GPI is
associated with an increased risk of thromboembolic events in
patients with SLE. Our data do not permit a definite conclusion
regarding the role of IgA anti-b2GPI in patients without SLE. We
also report that the presence of IgA anti-b2GPI is associated with
co-morbidities affecting organs involved in mucosal immunity.
Prospective studies of patients with IgA anti-b2GPI, isolated or in
association with other aPL, are needed to clarify the role of IgA
anti-b2GPI as a risk factor for thrombosis.
Acknowledgments
The authors would like to thank Tammy Utset and Amanda Schmitz for
their help.
Author Contributions
Conceived and designed the experiments: NJS JSL. Performed the
experiments: NJS RB RK DM FM TA SV MB MS AC JB JSL. Analyzed
the data: NJS RB RK DM FM TA SV MB MS AC JB JSL. Contributed
reagents/materials/analysis tools: NJS RB RK DM FM TA SV MB MS
AC JB JSL. Wrote the paper: NJS JSL.
References
1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, et al. (2006)
International consensus statement on an update of the classification criteria for
definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295–306.
2. Lee RM, Branch DW, Silver RM (2001) Immunoglobulin A anti-beta2-
glycoprotein antibodies in women who experience unexplained recurrent
spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 185:
748–753.
3. Lee SS, Cho ML, Joo YS, Hong YS, Min JK, et al. (2001) Isotypes of anti-beta2-
glycoprotein I antibodies: association with thrombosis in patients with systemic
lupus erythematosus. J Rheumatol 28: 520–524.
4. Escalante A, Brey RL, Mitchell BD Jr, Dreiner U (1995) Accuracy of
anticardiolipin antibodies in identifying a history of thrombosis among patients
with systemic lupus erythematosus. Am J Med 98: 559–565.
5. Selva-O’Callaghan A, Ordi-Ros J, Monegal-Ferran F, Martinez N, Cortes-
Hernandez F, et al. (1998) IgA anticardiolipin antibodies–relation with other
antiphospholipid antibodies and clinical significance. Thromb Haemost 79:
282–285.
6. Lakos G, Kiss E, Rege ´czy N, Tarja ´n P, Solte ´sz P, et al. (1999) Isotype
distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI)
antibodies: importance of IgA isotype. Clin Exp Immunol 117: 574–579.
7. Greco TP, Amos MD, Conti-Kelly AM, Naranjo JD, Ijdo JW (2000) Testing for
the antiphospholipid syndrome: importance of IgA anti-beta 2-glycoprotein I.
Lupus 9: 33–41.
8. Danowski A, Kickler TS, Petri M (2006) Anti-beta2-glycoprotein I: prevalence,
clinical correlations, and importance of persistent positivity in patients with
antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 33:
1775–1779.
9. Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, et al. (1998) IgA
class anti-beta2-glycoprotein I in patients with systemic lupus erythematosus.
J Rheumatol 25: 74–78.
10. Fanopoulos D, Teodorescu MR, Varga J, Teodorescu M (1998) High frequency
of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with
systemic lupus erythematosus: relationship with antiphospholipid syndrome.
J Rheumatol 25: 675–680.
11. Samarkos M, Davies KA, Gordon C, Loizou S (2006) Clinical significance of
IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic
lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol
25: 199–204.
12. Shen YM, Lee R, Frenkel E, Sarode R (2008) IgA antiphospholipid antibodies
are an independent risk factor for thromboses. Lupus 17: 996–1003.
13. Boin F, Franchini S, Colantuoni E, Rosen A, Wigley FM, et al. (2009)
Independent association of anti-beta[2]-glycoprotein I antibodies with macro-
vascular disease and mortality in scleroderma patients. Arthritis Rheum 60:
2480–2489.
14. Tajima C, Suzuki Y, Mizushima Y, Ichikawa Y (1998) Clinical significance of
immunoglobulin A antiphospholipid antibodies: possible association with skin
manifestations and small vessel vasculitis. J Rheumatol 25: 1730–1736.
15. Kumar S, Papalardo E, Sunkureddi P, Najam S, Gonza ´lez EB, et al. (2009)
Isolated elevation of IgA anti-beta2glycoprotein I antibodies with manifestations
of antiphospholipid syndrome: a case series of five patients. Lupus 18:
1011–1014.
16. Kawakami T, Yamazaki M, Mizoguchi M, Soma Y (2008) High titer of serum
antiphospholipid antibody levels in adult Henoch-Scho ¨nlein purpura and
cutaneous leukocytoclastic angiitis. Arthritis Rheum 59: 561–567.
17. Hodak E, Feuerman H, Molad Y, Monselise Y, David M (2003) Primary
anetoderma: a cutaneous sign of antiphospholipid antibodies. Lupus 12:
564–568.
18. Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA,
Hughes GR (2001) The value of IgA antiphospholipid testing for diagnosis of
antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
J Rheumatol 28: 2367–2373.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. (1982) The 1982
revised criteria for the classification of systemic lupus erythematosus. Arthritis
Rheum 25: 1271–1277.
20. Hochberg MC (1997) Updating the American College of Rheumatology revised
criteria for the classification of systemic lupus erythematosus [letter]. Arthritis
Rheum 140: 1725.
21. Romero-Diaz J, Garcia-Sosa I, Sanchez-Guerrero J (2009) Thrombosis in
systemic lupus erythematosus and other autoimmune diseases of recent onset.
J Rheumatol 36: 68–75.
22. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, et al. (2003) Premature
coronary-artery atherosclerosis in systemic lupus erythematosus. New Eng J Med
349: 2407–2415.
23. Levine JS, Branch DW, Rauch J (2002) Anti-phospholipid syndrome.
N Engl J Med 346: 752–763.
24. de Laat B, Derksen RH, Urbanus RT, de Groot PG (2005) IgG antibodies that
recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC,
and their presence correlates strongly with thrombosis. Blood 105: 1540–1545.
25. Dieude ´ M, Sene ´cal J-L, Raymond Y (2004) Induction of endothelial cell
apoptosis by heat-shock protein 60-reactive antibodies from anti-endothelial cell
autoantibody-positive systemic lupus erythematosus patients. Arthritis Rheum
50: 3221–3231.
26. Dieude ´ M, Correa J, Neville C, Pineau C, Levine JS, et al. (2009) Autoantibodies
to heat shock protein 60 are associated with arterial vascular events in patients
with anti-phospholipid antibodies. Arthritis Rheum 60: S766 (abstract).
aPLs and Thromboembolic Events
PLoS ONE | www.plosone.org 6 August 2010 | Volume 5 | Issue 8 | e12280